Idit Sagiv-Barfi

发表

In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma

R. Levy, D. Czerwinski, Idit Sagiv-Barfi, 2016 .

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

R. Levy, H. Kohrt, D. Czerwinski, 2015, Blood.

IMMUNOBIOLOGY Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD 20 antibodies

H. Kohrt, D. Czerwinski, É. Vivier, 2014 .

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

H. Kohrt, D. Czerwinski, É. Vivier, 2013, Blood.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Michael R. Green, H. Kohrt, R. Luong, 2013, The Journal of clinical investigation.

Radiotherapy and toll-like receptor agonists.

H. Kohrt, A. Marabelle, A. Filatenkov, 2015, Seminars in radiation oncology.

Targeting CD137 enhances the efficacy of cetuximab.

H. Kohrt, R. Houot, M. Goldstein, 2019, The Journal of clinical investigation.

S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock

A. Levitzki, T. Geiger, Y. Langut, 2018, The Journal of infectious diseases.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

J. Byrd, H. Kohrt, A. Johnson, 2014, Blood.

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

H. Kohrt, Idit Sagiv-Barfi, Lai Wang, 2014 .

Intratumoral immunotherapy relies on B and T cell collaboration

D. Czerwinski, Idit Sagiv-Barfi, J. Lohmeyer, 2022, Science Immunology.

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Hailing Lu, J. Meulen, Idit Sagiv-Barfi, 2015 .

Eradication of spontaneous malignancy by local immunotherapy

D. Czerwinski, S. Gambhir, S. Levy, 2018, Science Translational Medicine.

Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors.

A. Levitzki, Idit Sagiv-Barfi, E. Weiss, 2010, Bioorganic & medicinal chemistry.

An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory

D. Czerwinski, R. Waymouth, P. Wender, 2021, ACS central science.

An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory

D. Czerwinski, R. Waymouth, P. Wender, 2021, bioRxiv.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

H. Kohrt, D. Czerwinski, Idit Sagiv-Barfi, 2015, Proceedings of the National Academy of Sciences.

Imaging activated T cells predicts response to cancer vaccines

Emily M. Johnson, D. Czerwinski, S. Gambhir, 2018, The Journal of clinical investigation.

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

H. Kohrt, D. Czerwinski, H. Maecker, 2014 .

Targeting CD137 enhances the efficacy of cetuximab.

H. Kohrt, R. Houot, M. Goldstein, 2014, The Journal of clinical investigation.

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.

Mark M. Davis, J. Hamming, P. Quax, 2018, Cell stem cell.

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

D. Czerwinski, C. Bertozzi, J. Cochran, 2021, Cell chemical biology.

Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340)

Michael R. Green, H. Kohrt, R. Luong, 2013 .

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

J. Byrd, A. Johnson, N. Muthusamy, 2013 .

Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.

D. Czerwinski, W. Hong, Idit Sagiv-Barfi, 2022, Cancer Research.

768 Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice

D. Czerwinski, C. Bertozzi, J. Cochran, 2021, Journal for ImmunoTherapy of Cancer.

Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series

H. Kohrt, D. Czerwinski, G. Fine, 2014 .

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation

H. Kohrt, A. Szalay, N. Chen, 2014, Journal of Immunotherapy for Cancer.

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

H. Kohrt, C. Klein, D. Czerwinski, 2014 .

Targeting CD137 enhances the efficacy of cetuximab.

H. Kohrt, R. Houot, M. Goldstein, 2014, The Journal of clinical investigation.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

H. Kohrt, D. Czerwinski, Idit Sagiv-Barfi, 2015, Blood.